Literature DB >> 32407756

Clinical and conceptual comments on "Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis".

Rama Jayaraj1, Chellan Kumarasamy2, Sameep S Shetty3, Ravishankar Ram M4, Peter Shaw5.   

Abstract

Entities:  

Keywords:  Critical & mortal COVID-19; Meta-Analysis; Publication bias

Mesh:

Year:  2020        PMID: 32407756      PMCID: PMC7212981          DOI: 10.1016/j.jinf.2020.05.011

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Dear Editor, Currently research on COVID-19 has been prioritised globally with a high frequency of the articles being published in the literature. The incidence of false-negative tests for ‘happy hypoxia’ in asymptomatic patients, evolving epidemiological characteristics, and the universal risk of infection in every single age group with unpredictable capricious outcomes, explains the need to explore the risk factors associated with the novel coronavirus. The systematic review and meta-analysis on COVID-19 by Zheng et al. contribute to this global research output, and attempts to inform clinical decision making during this crisis. Nevertheless, there are a few recommendations that we would like to put forth in order to make the study robust enough to inform future decision making.

Few additional risk factors missing in the study

The epidemiology and clinical pattern of paediatric COVID 19 has a unique spectrum with infants and young children ≤ 5 years more likely to succumb to severe clinical symptoms of COVID19 than older children (i.e., ≥ 6 years). The immaturity of the immune system is cited as a plausible explanation. Children can swiftly progress to acute respiratory distress syndrome (ARDS). They may also have shock, encephalopathy, myocardial injury or heart failure, coagulation dysfunction, and acute kidney injury.

The forgotten “Cancer”

The unprecedented outbreak of COVID-19 has caused a substantial risk for cancer patients who are immunocompromised due to the disease and its treatment.

Fixed effect model of meta-analysis

We noted that the authors used the fixed-effect model to perform the meta-analysis. The fixed-effects model is practically applied when the studies across which the data is being pooled have, similar study parameters, and are devoid of any major heterogeneity. Hence, this model is often used to assess cohorts within a singular larger study. Nevertheless, the meta-analysis by Zhang et al., where multiple different studies are used, are inherently predisposed to heterogeneity due to the differential protocols and parameters of individual study. We propose the “random effects model” for this study. ,

Analysis of heterogeneity

Furthermore, although the analysis of heterogeneity was conducted using the commonly used I2 statistic, it may not have sufficient power by itself to determine between-study heterogeneity. The I2 statistic has shown to be limited in its application; nonetheless we recommend the authors also asses heterogeneity via the Cochran's Q statistic and the Tau statistic, which would add redundancy and robustness in the analysis of heterogeneity in this study.

Publication bias

We also note that the authors fail to perform an analysis of publication bias as a mandatory application towards a mutable research subject where the bias of publication is likely to exist. Furthermore, systematic review and meta-analysis guidelines mandate the assessment of publication bias. Hence an analysis of publication bias also proposed for this study in order to achieve concrete results that can impact the clinical decision making. We recommend the Eggers bias indicator test for lucid graphical assessment of publication bias.
  5 in total

1.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

2.  Meta-analysis of penile cancer: conceptual interpretations.

Authors:  Rama Jayaraj; Chellan Kumarasamy; Shanthi Sabarimurugan; Madurantakam Royam Madhav
Journal:  Lancet Oncol       Date:  2019-03       Impact factor: 41.316

3.  Conceptual, statistical and clinical interpretation of results from a systematic review and meta-analysis of prevalence of cervical HPV infection in women with SLE.

Authors:  Rama Jayaraj; Chellan Kumarasamy
Journal:  Autoimmun Rev       Date:  2019-02-11       Impact factor: 9.754

4.  Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis.

Authors:  Chellan Kumarasamy; Madurantakam Royam Madhav; Shanthi Sabarimurugan; Sunil Krishnan; Siddhartha Baxi; Ajay Gupta; K M Gothandam; Rama Jayaraj
Journal:  Cells       Date:  2019-07-25       Impact factor: 6.600

5.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.

Authors:  Zhaohai Zheng; Fang Peng; Buyun Xu; Jingjing Zhao; Huahua Liu; Jiahao Peng; Qingsong Li; Chongfu Jiang; Yan Zhou; Shuqing Liu; Chunji Ye; Peng Zhang; Yangbo Xing; Hangyuan Guo; Weiliang Tang
Journal:  J Infect       Date:  2020-04-23       Impact factor: 6.072

  5 in total
  3 in total

1.  COVID-19 in children: patiently and critically evaluate the scientific evidence.

Authors:  Nicole Ritz; J Peter de Winter
Journal:  Eur J Pediatr       Date:  2020-08       Impact factor: 3.183

2.  Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response.

Authors:  James Turnbull; Rakesh R Jha; Catherine A Ortori; Eleanor Lunt; Patrick J Tighe; William L Irving; Sameer A Gohir; Dong-Hyun Kim; Ana M Valdes; Alexander W Tarr; David A Barrett; Victoria Chapman
Journal:  J Infect Dis       Date:  2022-06-15       Impact factor: 7.759

3.  Clinical characteristics and outcomes of children with COVID-19 in Saudi Arabia.

Authors:  Abeer A Alnajjar; Ahmed M Dohain; Gaser A Abdelmohsen; Turki S Alahmadi; Zaher F Zaher; Abobakr A Abdelgalil
Journal:  Saudi Med J       Date:  2021-04       Impact factor: 1.484

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.